Welcome to our dedicated page for 22nd Century Group news (Ticker: $XXII), a resource for investors and traders seeking the latest updates and insights on 22nd Century Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 22nd Century Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 22nd Century Group's position in the market.
22nd Century Group, Inc. (XXII) will participate in the Aegis Capital Virtual Conference on May 9, 2024, focusing on nicotine harm reduction. The presentation will be held at 2:30 PM Eastern Time. Investors can access the live event online through the provided link.
22nd Century Group, Inc. (XXII) will announce its 2024 first quarter results on May 15, 2024, with a live webcast featuring the chairman and CEO Larry Firestone and CFO Dan Otto. The company focuses on tobacco harm reduction for health and wellness. The webcast will include financial reviews, progress updates, and a Q&A session.
22nd Century Group, Inc. (NASDAQ: XXII) eliminates $5.2 million of debt through an above-market equity transaction, enhancing the balance sheet, reducing interest expenses, and increasing shareholder equity. The company exchanged cash, common stock, and warrants with Omnia, aiming to become cash positive by Q1 2025. The transaction, detailed in an 8-K filing, restricts Omnia from owning more than 19.99% of common stock outstanding.
